Pharmaceuticals

InnoCare Announces Clearance by U.S. FDA of Clinical Trial of pan-TRK Inhibitor ICP-723

BEIJING, Aug. 30, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a commercial-stage biopharmaceutical company, announced today the Investigational New Drug (IND) clearance of its second-generation pan-TRK inhibitor ICP-723 by the US Food and Drug Administration (FDA) for starting phase I cli...

2021-08-31 08:30 2803

Through CEO of Hanmi Science, CancerRop Issues KRW 20 Billion New Shares for Cooperation with Oxford Vacmedix

SEOUL, South Korea, Aug. 30, 2021 /PRNewswire/ -- CancerRop (180400), a company specializing in precision medicine and molecular diagnostics, announced a jump start in the global vaccine hub for COVID-19 mRNA (messenger ribonucleic acid) with Hanmi Science through20 billion won worth of investmen...

2021-08-30 23:00 3548

I-Mab Announces Upcoming Participation at September Conferences

SHANGHAI and GAITHERSBURG, Md., Aug. 30, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in Septem...

2021-08-30 20:00 2016

GeneQuantum announces Dr. Yi Xia as Senior Vice President of Statistics and Data Science

SUZHOU, China, Aug. 29, 2021 /PRNewswire/ -- GeneQuantum Healthcare, an industry leading biopharmaceutical company dedicated to next generation bioconjugate drugs through innovative intelligent ligase-dependent conjugation (iLDC) technology platform, announces the appointment of Dr.Yi Xia as Seni...

2021-08-30 10:00 2253

InnoCare Releases 2021 Half Year Results and Business Highlights

BEIJING, Aug. 29, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2021 half year results which ended onJune 30, 2021. Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said, "On the fo...

2021-08-29 19:49 5004

IONOVA Life Science Announces New Financing Round of USD $100 Million

SHENZHEN, China, Aug. 27, 2021 /PRNewswire/ -- On August 27, 2021, Shenzhen IONOVA Life Science Co., Ltd. ("IONOVA" or "the company"), a clinical-stage biotechnology company located in theGuangdong-Hong Kong-Macao Greater Bay Area ofChina, announced completion of a new financing round of USD $100...

2021-08-27 22:00 3216

Laekna Therapeutics Receives IND Approvals in China and US for Phase Ib/III Global Multi-center Clinical Study of Afuresertib in combination with fulvestrant for patients with HR+/HER2- breast cancer

SHANGHAI and WAREN, New Jersey, Aug. 26, 2021 /PRNewswire/ -- Laekna Therapeutics announced today that the Center for Drug Evaluation (CDE), the National Medical Products Administration (NMPA) ofChina has approved the Investigational New Drug (IND) application of its Category 1 new drug candidate...

2021-08-27 11:20 1810

PharmaBlock Announces the Appointment of Dr. Xudong Wei as Senior Vice President to Lead and Enhance Small Molecule CDMO Services

NANJING, China, Aug. 26, 2021 /PRNewswire/ -- PharmaBlock (300725.SZSE), an innovative chemistry products and services provider to support drug discovery, development, and commercialization, announces the appointment of Dr.Xudong Wei as Senior Vice President and Head of CDMO Business to enhance s...

2021-08-26 23:00 4021

3SBio announces 2021 interim results, with strong growth in core businesses and significant progress in clinical development

HONG KONG, Aug. 26, 2021 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today unveiled its 2021 interim results. 3SBio maintained strong performance in core businesses, with core products occupying a leading market share. Meanwhile, the Company continuously increased ...

2021-08-26 22:09 6225

First patient treated in Clarity's Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial

SYDNEY, Aug. 25, 2021 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or the "Company"), an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing need in oncology, is pleased to announce that the first US patient has ...

2021-08-25 21:18 6274

Senhwa Biosciences Announces Dose Escalation Initiation of the Phase I Trial of Pidnarulex as a Treatment for Advanced Hematological Malignancies

TAIPEI and SAN DIEGO, Aug. 25, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focused on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, today announced the initiation of Dose Escalation within the Phase I Investigator Init...

2021-08-25 19:00 1910

Ocumension Acquires all the Equity Interests in Two Ophthalmic Products Mainland China, Further Enhancing its Pipeline Strength

HONG KONG, Aug. 25, 2021 /PRNewswire/ -- Beijing time, August 24, 2021, Ocumension Therapeutics announced that it has entered into a product acquisition agreement with a leading global pharmaceutical company Novartis, pursuant to which the Company will acquire all the equity interests in two oph...

2021-08-25 12:35 4015

GenScript Biotech Reports First Half 2021 Results

* In the first half of 2021, the Group reported a revenue of approximately USD 229.6 million, a 38.0% YoY increase, and a gross profit of USD 138.6 million , achieving a 28.1% YoY growth. All four of the Group's business segments demonstrated steady growth. * Building on early strategic invest...

2021-08-24 21:38 6678

Kintor Pharma to Report 2021 Interim Financial Results and Host Conference Call on August 30, 2021

SUZHOU, China, Aug. 24, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today the company will review the interim results and business highlights on...

2021-08-24 17:04 2573

Hepagene Therapeutics, Inc. Announces Positive Results from Phase I Trial of HPG1860

SHANGHAI, Aug. 23, 2021 /PRNewswire/ -- Hepagene Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on novel therapies for patients with liver diseases, today announced positive results from its Phase I study of HPG1860 conducted inthe United States. HPG1860 is a non-bile aci...

2021-08-23 22:00 1743

Roche and KeChow Reach a Cooperation Agreement

SHANGHAI, Aug. 20, 2021 /PRNewswire/ -- On August 2, 2021, Shanghai Roche Pharmaceuticals Co., Ltd. (hereinafter referred to as "Roche Pharma China" or "Roche") and Shanghai KeChow Pharma, Inc. (hereinafter referred to as "KeChow Pharma" or "KeChow") entered into a cooperation agreement to improv...

2021-08-20 23:00 3471

Daewoong Pharmaceutical and Hanall Biopharma Invest $1M USD in Alloplex Biotherapeutics

SEOUL, South Korea, Aug. 19, 2021 /PRNewswire/ -- Daewoong Pharmaceutical and Hanall Biopharma ofSouth Korea are expanding their global open collaboration initiative by investing in Alloplex Biotherapeutics, an emergingBoston-based biotechnology company.

2021-08-19 21:00 2697

PharmAbcine Announces Submission of PCT for an Anti-ANG2 Antibody for the Treatment of Ocular Diseases

DAEJEON, South Korea, Aug. 19, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, today announced it submitted a Patent Cooperation Treaty (PCT), an international patent application, for ...

2021-08-19 20:00 1581

I-Mab Announces Establishment of Environmental, Social and Governance Committee

* I-Mab received highest first-time ESG rating among China-based biotech companies from MSCI * New majority independent ESG committee to set overall ESG strategies for the Company * Women account for two-thirds of the total workforce and over 30% of I-Mab's Board of Directors * Committed ...

2021-08-19 19:00 4650

Senhwa's Silmitasertib Receives US FDA Fast Track Designation for the Treatment of Recurrent Sonic Hedgehog Driven Medulloblastoma

TAIPEI and SAN DIEGO, Aug. 18, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focused on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, today announced that the US Food and Drug Administration (FDA) has granted Fast Tr...

2021-08-19 10:57 1960
1 ... 135136137138139140141 ... 151

Week's Top Stories